Kiadis Pharma NV (LTS:0RBP) EV-to-FCF : -8.45 (As of May. 25, 2024)

Kiadis Pharma NV EV-to-FCF Chart

Kiadis Pharma NV Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
EV-to-FCF		Get a 7-Day Free Trial				-8.20	-8.25	-6.41	-1.23	-8.19

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
EV-to-FCF	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Kiadis Pharma NV's EV-to-FCF

For the Biotechnology subindustry, Kiadis Pharma NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiadis Pharma NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's EV-to-FCF falls into.

Kiadis Pharma NV EV-to-FCF Calculation

Kiadis Pharma NV's EV-to-FCF for today is calculated as:

Kiadis Pharma NV's current Enterprise Value is €220.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kiadis Pharma NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2020 was €-26.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiadis Pharma NV  (LTS:0RBP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Kiadis Pharma NV's PE Ratio (TTM) for today is calculated as:

Kiadis Pharma NV's share price for today is €5.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kiadis Pharma NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was €-2.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Kiadis Pharma NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (LTS:0RBP) Business Description